MidFirst Bank’s United Therapeutics UTHR Stock Holding History

MidFirst Bank’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71K	Hold	5	–	–	﹤0.01%	655
2026 Q1	$2.96K	Buy	+5	New	+$2.49K	﹤0.01%	635

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

MidFirst Bank's UTHR Position: Q2 2026 in Review

MidFirst Bank held its United Therapeutics (UTHR) position steady in Q2 2026 at 5 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #655.

MidFirst Bank first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.96K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

MidFirst Bank held 5 shares of United Therapeutics worth $2.71K as of Q2 2026.
MidFirst Bank left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up ﹤0.01% of MidFirst Bank's portfolio in Q2 2026, its #655 holding.
MidFirst Bank first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
MidFirst Bank's United Therapeutics position peaked at $2.96K in Q1 2026.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on MidFirst Bank's 13F filing for Q2 2026, filed 7 Aug 2026.